Hologic, Inc. (NASDAQ:HOLX) Given Consensus Rating of "Hold" by Brokerages

Shares of Hologic, Inc. (NASDAQ:HOLX - Get Free Report) have been assigned a consensus recommendation of "Hold" from the seventeen ratings firms that are currently covering the stock, Marketbeat.com reports. Eleven equities research analysts have rated the stock with a hold recommendation, five have assigned a buy recommendation and one has issued a strong buy recommendation on the company. The average 1 year target price among analysts that have covered the stock in the last year is $77.42.

HOLX has been the topic of a number of research reports. Raymond James restated an "outperform" rating and set a $71.00 price target (down previously from $90.00) on shares of Hologic in a research note on Friday, May 2nd. Needham & Company LLC restated a "hold" rating on shares of Hologic in a research report on Tuesday, May 27th. Citigroup cut their target price on shares of Hologic from $80.00 to $70.00 and set a "neutral" rating on the stock in a report on Tuesday, March 4th. Morgan Stanley decreased their price target on shares of Hologic from $77.00 to $65.00 and set an "equal weight" rating for the company in a research note on Monday, May 5th. Finally, Stephens lowered their price objective on shares of Hologic from $77.00 to $70.00 and set an "overweight" rating on the stock in a research report on Tuesday, May 13th.

Hologic Trading Down 0.7%

NASDAQ HOLX opened at $64.75 on Friday. Hologic has a 52 week low of $51.90 and a 52 week high of $84.67. The firm has a 50 day moving average of $58.70 and a two-hundred day moving average of $64.86. The company has a quick ratio of 2.78, a current ratio of 3.49 and a debt-to-equity ratio of 0.52. The stock has a market capitalization of $14.43 billion, a PE ratio of 20.43, a price-to-earnings-growth ratio of 2.14 and a beta of 0.55.

Hologic (NASDAQ:HOLX - Get Free Report) last released its quarterly earnings data on Thursday, May 1st. The medical equipment provider reported $1.03 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.02 by $0.01. The business had revenue of $1.01 billion during the quarter, compared to analysts' expectations of $1 billion. Hologic had a return on equity of 19.72% and a net margin of 18.42%. The business's quarterly revenue was down 1.2% compared to the same quarter last year. During the same period in the prior year, the firm posted $1.03 EPS. As a group, research analysts expect that Hologic will post 4.28 EPS for the current fiscal year.

Insider Buying and Selling at Hologic

In other news, Director Martin D. Madaus purchased 5,445 shares of the company's stock in a transaction that occurred on Wednesday, May 7th. The shares were purchased at an average price of $55.24 per share, with a total value of $300,781.80. Following the purchase, the director now directly owns 5,445 shares of the company's stock, valued at approximately $300,781.80. This represents a ∞ increase in their position. The transaction was disclosed in a filing with the SEC, which can be accessed through this link. 1.88% of the stock is currently owned by corporate insiders.

Institutional Trading of Hologic

Hedge funds have recently made changes to their positions in the stock. Victory Capital Management Inc. grew its stake in Hologic by 34.4% in the first quarter. Victory Capital Management Inc. now owns 6,609,728 shares of the medical equipment provider's stock worth $408,283,000 after purchasing an additional 1,692,177 shares in the last quarter. Geode Capital Management LLC lifted its holdings in Hologic by 2.6% during the 4th quarter. Geode Capital Management LLC now owns 5,732,131 shares of the medical equipment provider's stock worth $412,159,000 after buying an additional 144,838 shares during the last quarter. Invesco Ltd. increased its stake in Hologic by 18.8% during the first quarter. Invesco Ltd. now owns 4,834,957 shares of the medical equipment provider's stock valued at $298,655,000 after purchasing an additional 764,573 shares during the last quarter. Mitsubishi UFJ Asset Management Co. Ltd. grew its position in shares of Hologic by 1.6% during the 1st quarter. Mitsubishi UFJ Asset Management Co. Ltd. now owns 4,473,098 shares of the medical equipment provider's stock valued at $276,303,000 after buying an additional 69,878 shares during the last quarter. Finally, Boston Partners raised its position in shares of Hologic by 81.0% during the 4th quarter. Boston Partners now owns 3,580,519 shares of the medical equipment provider's stock worth $257,959,000 after purchasing an additional 1,602,463 shares during the period. Institutional investors and hedge funds own 94.73% of the company's stock.

Hologic Company Profile

Hologic, Inc develops, manufactures, and supplies diagnostics products, medical imaging systems, and surgical products for women's health through early detection and treatment. The company operates through four segments: Diagnostics, Breast Health, GYN Surgical, and Skeletal Health. It provides Aptima molecular diagnostic assays to detect the infectious microorganisms; Aptima viral load assays for Hepatitis B virus, Hepatitis C virus, human immunodeficiency virus, and human cytomegalo virus; Aptima bacterial vaginosis and candida vaginitis assays for the diagnosis of vaginitis; Aptima SARS-CoV-2 and Panther Fusion SARS-CoV-2 assays to detect SARS-CoV-2; ThinPrep System for cytology applications; and Rapid Fetal Fibronectin Test that assists physicians in assessing the risk of pre-term birth.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.